Directorate Change
08 7월 2008 - 5:31PM
UK Regulatory
RNS Number : 5435Y
Phosphagenics Limited
08 July 2008
08 July 2008
Company Announcement
Phosphagenics appoints US-based Non-Executive Director
Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced the appointment of Michael Ashton as a
Non-Executive Director. In addition to joining the Board of Directors, he will also consult to the Company on commercialisation strategies.
Michael has more than 30 years' experience in the international pharmaceutical industry having held senior management positions with
Merck Inc., Pfizer Inc., Faulding Inc. and SkyePharma Plc, where he was CEO.
He is a member of the Boards of Hikma Plc., Proximagen Neuroscience Plc. and Transition Therapeutics Inc.
Harry Rosen, Phosphagenics' President & CEO, said: "I am delighted to welcome Michael to our Board and believe his appointment
considerably strengthens our commercial team."
Michael Ashton said: "The Company's technologies and new product development opportunities are very exciting. I am very pleased to be
joining the Board at this time."
Pursuant to Rule 17, Schedule Two, Paragraph (g) of the AIM Listing Rules for Companies, the Company discloses the following information
in relation to Mr M R D Ashton who, with effect from 8 July 2008, has been appointed as a Non-Executive Director of the Company:
(i) the director's full name and age together with any previous names;
Michael Richard Dwyer ASHTON born in Sydney, NSW, Australia on 21 February 1946
(ii) the names of all companies and partnerships of which the director has been a
director or partner at any time in the previous five years, indicating whether or not
the director is still a director or partner;
COMPANY NAME APPOINTED STATUS
Hikma Plc Nov 2005 Current
Proximagen Plc Dec 2005 Current
Transition Inc Dec 2002 Current
LMANV Dec 2006 Retired July 2007
Skyepharma Plc Mar 1997 Retired June 2006
Somanta Inc Jun 2005 Retired December 2007
The Company, Phosphagenics Limited, confirms that there is no further disclosure obligation required pursuant to Rule 17, Schedule Two,
Paragraph (g)
ENDS*.
APPENDIX AND NOTES TO EDITORS
About Phosphagenics Limited
Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to
enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.
Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a
phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well
as to assist in the production of drug delivery platforms.
Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market
(PSG). An ADR - Level 1 program was established in the U.S. with The Bank of New York Mellon (PPGNY) for U.S. investors to trade in
Phosphagenics' stock on the 'over-the-counter' market. In July 2007, this was upgraded to the International OTCQX, a new premium market tier
in the U.S. for international exchange-listed companies, operated by Pink Sheets, LLC.
For more information, please visit Phosphagenics website at www.phosphagenics.com
Company Contact Details: U.S. Investor and Media Contacts:
Mr Harry Rosen Brian Ritchie
Phosphagenics Limited Financial Dynamics
President & CEO Tel +1 212 850 5683
Tel +61 3 9605 5900
Mary McSwiggan
Phosphagenics Limited
Investor Relations Manager
Tel +61 3 9605 5907
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAVVLBBVDBLBBK
Phosphagen. (LSE:PSG)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Phosphagen. (LSE:PSG)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Phosphagen. (London Stock Exchange)의 실시간 뉴스: 최근 기사 0
More Phosphagenics Ltd News Articles